Immunotherapy News and Research

Latest Immunotherapy News and Research

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAA), while fire ant allergy sufferers know allergy shots can save their life, more than 60 percent do not adhere to treatment guidelines.

4 Mar 2013

DBV Technologies total revenues increase to €2,776,588 for full year 2012

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March 1st, 2013.

4 Mar 2013

Older patients with head and neck cancers less likely to die in high-volume hospitals

A study of older patients with advanced head and neck cancers has found that where they were treated significantly influenced their survival.

4 Mar 2013

Novel immunotherapy could potentially work like a vaccine against metastatic cancers

Preclinical, laboratory studies suggest a novel immunotherapy could potentially work like a vaccine against metastatic cancers, according to scientists at Virginia Commonwealth University Massey Cancer Center.

28 Feb 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

BCHE gene variant predicts extent of plaque deposits in Alzheimer's

A study combining genetic data with brain imaging, designed to identify genes associated with the amyloid plaque deposits found in Alzheimer's disease patients, has not only identified the APOE gene -- long associated with development of Alzheimer's -- but has uncovered an association with a second gene, called BCHE.

21 Feb 2013

Four genetic variations may increase risk of colorectal cancer

An international research team co-led by cancer prevention researcher Ulrike "Riki" Peters, Ph.D., M.P.H., and biostatistician Hsu Li, Ph.D., at Fred Hutchinson Cancer Research Center has identified variations in four genes that are linked to an increased risk of colorectal cancer.

21 Feb 2013

Immunotherapy could be answer to treating novel coronavirus

Investigation into the mechanism of action of the novelcoronavirus HCoV-EMC, which recently emerged in the Middle East, has revealed that although human bronchial epithelia are very susceptible to infection with the virus, interferon I and III were both able to significantly reduce its replication in cell culture.

20 Feb 2013

Internationally-recognized cancer clinician named first K. Hasumi Professor of Medical Oncology

Internationally-recognized cancer clinician and researcher Takami Sato, M.D., Ph.D., who serves as the Director of the Metastatic Uveal Melanoma Program in the Department of Medical Oncology at Thomas Jefferson University, has been named the first K. Hasumi Professor of Medical Oncology.

20 Feb 2013

New coronavirus could potentially be treated with immunotherapy

The new coronavirus that has emerged in the Middle East is well-adapted to infecting humans but could potentially be treated with immunotherapy, according to a study to be published on February 19 in mBio-, the online open-access journal of the American Society for Microbiology.

20 Feb 2013

Third Rock Ventures announces formation of Jounce Therapeutics

Third Rock Ventures, LLC today announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is focused on the discovery and development of first-in-class cancer immunotherapies designed to harness the patient's immune system to seek out and attack cancerous cells and tumors.

15 Feb 2013

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.

13 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

CEL-SCI reports net loss of $2,310,246 for fiscal quarter ended December 31, 2012

CEL-SCI Corporation reports financial results for the fiscal quarter ended December 31, 2012.

10 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

Sneezing and wheezing are common among people living close to the equator

Those living near the equator may find themselves sneezing and wheezing more than usual. And the reason may not be due to increasing pollen counts.

4 Feb 2013

Scientists identify cause of certain forms of epilepsy in cats

There is something sinister about epilepsy: the disease affects the very core of our being, our brain. Epileptic attacks can lead to seizures throughout the body or in parts of it. Clouding of consciousness or memory lapses are also possible. The causes are still only partially understood but in some cases brain tumours, infections, inflammations of the brain or metabolic diseases have been implicated.

2 Feb 2013

Two-step personalized immunotherapy safe for patients with ovarian cancer

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment - a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy - triggers anti-tumor immune responses in these type of patients.

1 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

DBV Technologies total revenues increase to €2,776,588 for full year 2012

Older patients with head and neck cancers less likely to die in high-volume hospitals

Novel immunotherapy could potentially work like a vaccine against metastatic cancers

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Circassia announces results from ToleroMune cat allergy phase II clinical study

BCHE gene variant predicts extent of plaque deposits in Alzheimer's

Four genetic variations may increase risk of colorectal cancer

Immunotherapy could be answer to treating novel coronavirus

Internationally-recognized cancer clinician named first K. Hasumi Professor of Medical Oncology

New coronavirus could potentially be treated with immunotherapy

Third Rock Ventures announces formation of Jounce Therapeutics

Researchers investigate new avenue of treatment to help boost poor pancreatic cancer survival rates

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

CEL-SCI reports net loss of $2,310,246 for fiscal quarter ended December 31, 2012

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Sneezing and wheezing are common among people living close to the equator

Scientists identify cause of certain forms of epilepsy in cats

Two-step personalized immunotherapy safe for patients with ovarian cancer

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in